Last reviewed · How we verify
NCT05054933
Ultrasound Capsule Endoscopy for Esophagus Examination
NA trial testing ultrasound capsule endoscopy in Esophageal Diseases in 20 participants. Status unknown.
30 May 2022
Quick facts
| Lead sponsor | Changhai Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 26 September 2021 |
| Primary completion | 30 May 2022 |
| Estimated completion | 30 July 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- ultrasound capsule endoscopy
Conditions studied
- Esophageal Diseases — all drugs for Esophageal Diseases →
Sponsor
Changhai Hospital
Who can join
18 and older, any sex, with Esophageal Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this pilot study is to assess the feasibility and safety of the clinical application of ultrasound capsule endoscopy in esophageal examination compared with conventional endoscopic ultrasound examination.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New US capsule endoscopy for superficial and submucosal imaging of the esophagus: the first-in-human study.
Qiu XO, Jiang X, Chen YZ, Xia JS, et al · · 2023 · cited 2× · PMID 37356634 · DOI 10.1016/j.gie.2023.06.015
Verify or expand the search:
- PubMed search for NCT05054933
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Diseases
Currently open trials in the same condition.
- NCT06721520 — Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy · Phase 2, PHASE3 · recruiting
- NCT06835374 — Comparative Assessment of Esophagitis in Cases With and Without Esophageal Motility Disorders: A Prospective Study · NA · recruiting
- NCT06870630 — Standard Versus Oesophago-gastric Junction Complex Myotomy for Treatment naïve Type 2 Achalasia Patients · NA · recruiting
- NCT05624099 — Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. · Phase 2 · recruiting
- NCT06514079 — Role of Topical Steroid Injection With Refractory Benign Esophageal Stricture Endoscopic Dilatation in Children · NA · recruiting
Other Changhai Hospital trials
Trials by the same sponsor.
- NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
- NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05054933 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
- Last refreshed: 1 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05054933.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing